Clinical trials targeting aging and age-related multimorbidity

Journals of Gerontology - Series A Biological Sciences and Medical Sciences

Volumn 72, Issue 3, 2017, Pages 355-361

  Espeland, Mark A ^a   Crimmins, Eileen M ^b   Grossardt, Brandon R ^c   Crandall, Jill P ^d   Gelfond, Jonathan A L ^e   Harris, Tamara B ^f   Kritchevsky, Stephen B ^a   Manson, Joann E ^g   Robinson, Jennifer G ^h   Rocca, Walter A ^c,i   Temprosa, Marinella ^j   Thomas, Fridtjof ^k   Wallace, Robert ^h   Barzilai, Nir ^d  

^a WAKE FOREST SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF SOUTHERN CALIFORNIA   (United States)

^c MAYO CLINIC   (United States)

^d ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^e UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

^f NATIONAL INSTITUTE ON AGING   (United States)

^g BRIGHAM AND WOMEN S HOSPITAL   (United States)

^h UNIVERSITY OF IOWA   (United States)

ⁱ University of Iowa Carver College of Medicine ^*  (United States)

^j GEORGE WASHINGTON UNIVERSITY   (United States)

^k UNIVERSITY OF TENNESSEE HEALTH SCIENCE CENTER   (United States)

more..

Author keywords

Chronic diseases; Clinical trial design; Geroscience

Indexed keywords

AGE; AGED; AGING; CHRONIC DISEASE; CLINICAL TRIAL (TOPIC); COMORBIDITY; DISEASE COURSE; FEMALE; HUMAN; INCIDENCE; MALE; VERY ELDERLY;

AGE FACTORS; AGED; AGED, 80 AND OVER; AGING; CHRONIC DISEASE; CLINICAL TRIALS AS TOPIC; COMORBIDITY; DISEASE PROGRESSION; FEMALE; HUMANS; INCIDENCE; MALE;

EID: 85016185737     PISSN: 10795006     EISSN: 1758535X     Source Type: Journal    
DOI: 10.1093/gerona/glw220     Document Type: Article

References (37)

1. St Sauver JL, Boyd CM, Grossardt BR, et al. Risk of developing multimorbidity across all ages in an historical cohort study: differences by sex and ethnicity. BMJ Open. 2015;5:e006413. doi:10.1136/bmjopen-2014-006413
2. Kochanek KD, Murphy SL, Xu JQ, Tejada-Vera B. Deaths: final data for 2014. National Vital Statistics Reports. Vol 65, No 4. Hyattsville, MD: National Center for Health Statistics; 2016.
3. Miller RA. Extending life: scientific prospects and political obstacles. Milbank Q. 2002;80:155-174.
4. Goldman DP, Cutler D, Rowe JW, et al. Substantial health and economic returns from delayed aging may warrant a new focus for medical research. Health Affairs. 2013;32:1698-1705.
5. Fabbri E, Zoli M, Gonzalez-Freire M, Salive M, Studenski SA, Ferrucci L. Aging and multimorbidity: new tasks, priorities, and frontiers for integrated gerontological and clinical research. JAMDA. 2015;16:640-647.
6. Lochner KA, Goodman RA, Posner S, Parekh A. Multiple chronic conditions among Medicare beneficiaries: state-level variations in prevalence, utilization, and cost, 2011. Medicare Medicare Res Rev. 2013;3. doi:10.5600/mmrr.003.03.b02
7. Goodman RA, Posner SF, Huang ES, Parekh AK, Koh HK. Defining and measuring chronic conditions: imperatives for research, policy, program, and practice. Prev Chronic Dis. 2013;10:E66. doi:10.5888/pcd10.120239
8. Tinetti ME, McAvay G, Trentalange M, Cohen AB, Allore HG. Association between guideline recommended drugs and death in older adults with multiple chronic conditions: population based cohort study. BMJ. 2015;351:h4984. doi:10.1136/bmj.h4984
9. Bartke A, Wright JC, Mattison JA, Ingram DK, Miller RA, Roth GS. Extending the lifespan of long-lived mice. Nature. 2001;414:412. doi:10.1038/35106646
10. Barzilai N, Huffman DM, Muzumdar RH, Bartke A. The critical role of metabolic pathways in aging. Diabetes. 2012;61:1315-1322. doi:10.2337/db11-1300
11. Longo VD, Antebi A, Bartke A, et al. Interventions to slow aging in humans: Are we ready? Aging Cell. 2015;14:497-510. doi:10.1111/acel.12338
12. Barzilai N, Crandall JP, Kritchevsky SB, Espeland MA. Metformin as a tool to target aging. Cell Metab. 2016;23:1060-1065. doi:10.1016/j. cmet.2016.05.011
13. Miller RA, Harrison DE, Astle CM, et al. An aging interventions testing program: study design and interim report. Aging Cell. 2007;6:565-575. doi:10.1111/j.1474-9726.2007.00311.x
14. Nadon NL, Strong R, Miller RA, et al. Design of aging intervention studies: the NIA Interventions Testing Program. Age. 2008;30:187-199.
15. Katz S, Branch LG, Branson MH, Beck JC, Greer DS. Active life expectancy. NEJM. 1983;309:1218-1224.
16. Crimmins EM, Saito Y, Ingegneri D. Changes in life expectancy and disability-free life expectancy in the United States. Pop Develop Rev. 1989;15:235-267.
17. Salida D, Solomon D, Rubenstein L, et al. Feasibility of quality indicators for the management of geriatric syndromes in nursing home residents. JAMDA. 2005;6:S50-S69.
18. Inouye SK, Studenski S, Tinetti ME, Kuchel GA. Geriatric syndromes: clinical, research, and policy implications of a core geriatric concept. J Am Geriatr Soc. 2007;55:780-791. doi:10.1111/j.1532-5415.2007.01156.x
19. Marengoni A, Angleman S, Melis R, et al. Aging with multimorbidity: a systematic review of the literature. Ageing Res Rev. 2011;10:430-439. doi:10.1016/j.arr.2011.03.003
20. Allore HG, Zhan Y, Tinetti M, Trentalange M, McAvay G. Longitudinal average attributable fraction as a method for studying time-varying conditions and treatments on recurrent self-rated health: the case of medications in older adults with multiple chronic conditions. Ann Epidemiol. 2015;25:681.e4-686.e4. doi:10.1016/j.annepidem.2015.03.022
21. Charlson ME, Charlson RE, Peterson JC, et al. The Charlson comorbidity index is adapted to predict costs of chronic diseases in primary care patients. J Clin Epidemiol. 2008;61:1234-1244.
22. Ayers E, Verghese J. Motoric cognitive risk syndrome and risk of mortality in older adults. Alz Dement. 2015;S1552-S1560.
23. Stepanova M, Rodriguez E, Birerdinc A, Baranova A. Age-independent rise of inflammatory scores may contribute to accelerated aging in multi-morbidity. Oncotarget. 2015;6:1414-1421. doi:10.18632/oncotarget.2725
24. Kooman JP, Broers NJ, Usvyat L, et al. Out of control: accelerated aging in uremia. Nephrol Dial Transplant. 2013;28:48-54. doi:10.1093/ndt/gfs451
25. Wikström K, Lindström J, Harald K, Peltonen M, Laatikainen T. Clinical and lifestyle-related risk factors for incident multimorbidity: 10-year follow-up of Finnish population-based cohorts 1982-2012. Eur J Intern Med. 2015;26:211-216. doi:10.1016/j.ejim.2015.02.012
26. Sonnega A, Faul JD, Ofstedal MB, Langa KM, Phillips JW, Weir DR. Cohort profile: the Health and Retirement Study (HRS). Int J Epidemiol. 2014;43:576-585. doi:10.1093/ije/dyu067
27. Rocca WA, Yawn BP, St Sauver JL, Grossardt BR, Melton LJ 3rd. History of the Rochester Epidemiology Project: half a century of medical records linkage in a US population. Mayo Clin Proc. 2012;87:1202-1213. doi:10.1016/j.mayocp.2012.08.012
28. Women's Health Initiative Study Group. Design of the Women's Health Initiative Clinical Trial and Observational Study. Cont Clin Trials. 1998;19:61-109.
29. Heckbert SR, Kooperberg C, Safford MM, et al. Comparison of selfreport, hospital discharge codes, and adjudication of cardiovascular events in the Women's Health Initiative. Am J Epidemiol. 2004;160:1152-1158. doi:10.1093/aje/kwh314
30. Ferreira-Gonzalez I, Permanyer-Miralda G, Busse JW, et al. Methodologic discussions for using and interpreting composite endpoints are limited, but still identify major concerns. J Clin Epidemiol. 2007;60:651-657.
31. Parner TE. A composite likelihood approach to multivariate survival data. Scand J Stat. 2001;28:295-302.
32. Tibaldi F, Molenberghs G, Burzykowski T, Geys H. Pseudo-likelihood estimation for a marginal multivariate survival model. Stat Med. 2004;23:947-963. doi:10.1002/sim.1664
33. Pogue J, Devereaux PJ, Thabane L, Yusuf S. Designing and analyzing clinical trials with composite outcomes: consideration of possible treatment differences between the individual outcomes. PLoS One. 2012;7:e34785. doi:10.1371/journal.pone.0034785
34. Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J. 2012;33:176-182. doi:10.1093/eurheartj/ehr352
35. Chen YH, DeMets DL, Lan KK. Monitoring mortality at interim analyses while testing a composite endpoint at the final analysis. Control Clin Trials. 2003;24:16-27.
36. Pecina MJ, et al. Adjustment for competing causes of mortality influences trial endpoints other than total mortality. Circulation. 2009;119:3078-3084.
37. Little RJ, D'Agostino R, Cohen ML, et al. The prevention and treatment of missing data in clinical trials. N Engl J Med. 2012;367:1355-1360. doi:10.1056/NEJMsr1203730